Oligonucleotides to Inhibit KRAS for Pancreatic Ductal AdenoCarcinoma is under clinical development by Codiak BioSciences and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Oligonucleotides to Inhibit KRAS for Pancreatic Ductal AdenoCarcinoma LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oligonucleotides to Inhibit KRAS for Pancreatic Ductal AdenoCarcinoma overview
Oligonucleotides are under development for the treatment of pancreatic ductal adenocarcinoma. It is administered through intravenous route. The therapeutic candidate comprises genetically altered exosomes called as iexosomes which are used for the delivery of KRAS-specific targeting genetic material such as short interfering RNA or short hairpin RNA. These iexosomes acts by targeting mutant KRAS or oncogenic KRas.
Codiak BioSciences overview
Codiak BioSciences is an exosome therapeutics company. The company focuses on the development of proprietary pipeline of targeted medicines for diseases with unmet medical needs. Its engEx platform capitalizes on exosomes, which are nanometer-sized membrane sacs that delivers proteins, lipids, nucleic acids, and small molecules to various cell types. Codiak BioSciences latest pipeline products includes exoSTING, exoIL-12, exoASO-STAT6, oncogene targets, exoASO-NLRP3, gene targets, exoVACC and exoASO-NRAS. The company also has rights to a novel investigational drug candidate for the treatment of pancreatic cancer, from The University of Texas, MD Anderson Cancer Center. Codiak BioSciences is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Oligonucleotides to Inhibit KRAS for Pancreatic Ductal AdenoCarcinoma’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
